Miln-Avenir

/ BioAvenir Ltd.

The usual dose is 1 capsule of 50 mg in the morning and 1 capsule of 50 mg in the evening, preferably with a meal.
In case of renal insufficiency, the recommended dose is reduced according to the degree of alteration in renal function. In this case, use the 25 mg capsules.
Treatment duration
As with any antidepressants, the efficacy of this drug only becomes apparent after a certain delay which can vary from 1 to 3 weeks.
Treatment with Milnacipran should be discontinued gradually.

For treatment of depression in adults above the age of 18 years.

This medicine must never be used in the following cases:
•  hypersensitivity to the active substance or to any of the excipients
• association with irreversible MAO inhibitors, B selective MAO inhibitors, digitalis and 5HT1D agonists (sumatriptan, etc.)
• lactation
• uncontrolled hypertension, severe or unstable coronary heart disease as these underlying conditions may be compromised by increases in blood pressure or heart rate.
Generally, this medication should not be used in the following cases:
• In association with epinephrine and norepinephrine by parenteral route, clonidine and related compounds and A selective MAO inhibitors
• Prostatic hypertrophy and other genito-urinary disorders

Please refer to the license holder for further details.

Very common: Headache, nausea.
Common: Agitation, anxiety, depression, eating disorders, sleep disorders, suicidal behavior, migraine, tremor, dizziness, dysesthesia, somnolence, tachycardia,
palpitations, hot flush hypertension, constipation, diarrhoea, abdominal pain, dyspepsia, vomiting, dry mouth, pruritus – rash, hyperhidrosis, musculoskeletal pain, dysuria – pollakiuria, ejaculation disorders, erectile dysfunction, testicular pain, fatigue.
Please refer to the license holder for further details.

Please refer to the license holder for further details.

Pregnancy:
There are no adequate data from the use in pregnant women. Animal studies have shown reproductive toxicity. Neonatal risk after pregnancy exposure with serotonin re-uptake inhibitors have been reported and may be related to either withdrawal syndrome or serotonin toxicity: tachypnea, feeding difficulties, tremors, hypertonicity or hypotonia, sleeping disorders, hyperexcitability or more rarely long- lasting crying. All these signs appear in the first days of life and are generally of short duration and not severe. Consequently, as a precautionary measure, it is preferable to avoid this medicinal product during pregnancy and in women of childbearing potential not using contraception. Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRI/SNRI exposure within the month prior to birth.
Breast-feeding:
Because small amounts of this drug are excreted in breast-milk, breast-feeding is contraindicated.

Please refer to the license holder for further details.